Focused On-demand Library for T-cell leukemia/lymphoma protein 1A

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P56279

UPID:

TCL1A_HUMAN

Alternative names:

Oncogene TCL-1; Protein p14 TCL1

Alternative UPACC:

P56279; Q6IBK7

Background:

T-cell leukemia/lymphoma protein 1A, also known as Oncogene TCL-1 and Protein p14 TCL1, plays a pivotal role in cellular processes. It enhances the phosphorylation and activation of AKT1, AKT2, and AKT3, promoting AKT1's nuclear translocation. This activity is crucial for cell proliferation, stabilization of mitochondrial membrane potential, and cell survival.

Therapeutic significance:

Understanding the role of T-cell leukemia/lymphoma protein 1A could open doors to potential therapeutic strategies. Its involvement in key signaling pathways highlights its potential as a target for therapeutic intervention in diseases where these pathways are dysregulated.